05 Sep 2013, BioSpectrum Bureau , BioSpectrum
Singapore: RSA, the leading global life sciences executive search and interim management specialist, has appointed Mr Chris Molloy as CEO.
Mr Molloy brings to RSA over 20 years' experience of international life sciences across pharmaceuticals, biotechnology and start-up sectors. Chris began his career with Glaxo, where he held a range of management, research, business change and scientific collaboration roles. Moving to Asia in 2004 he became COO of the award-winning emerging biotech firm MerLion
Pharmaceuticals, where he was also responsible for fundraising and business development.
Most recently he has been VP corporate development and marketing at IDBS, which has secured a global leadership position in enterprise R&D software. In addition to a range of technology development and biotech advisory roles, Chris has also been a non-executive member of the RSA board since 2009. Chris will retain his active scientific role in the pre-clinical development and licensing of new medicines for HIV with KFLP Biotech, a ‘virtual' US R&D company.
Mr Chris said that, "I am delighted to be joining the executive team at RSA The Life Sciences industry is undergoing seismic change: one in which high quality people are the key asset for success. Helping life sciences organiszations identify the most transformational people is a skill and a privilege. RSA provides a trusted resource to our clients, allowing them to focus on things that only they can do: select the best people for their future. I have enjoyed working with Mr Nick Stephens and the board over the past four years and I look forward to helping RSA continue to thrive."
Mr Nick Stephens, executive chairman, RSA, said that, "The time has come to prepare for the next step in our evolution. We are excited to have Chris on board as RSA's CEO. He will continue to preserve the special culture and feel of RSA whilst making ourselves even more professional as an executive search and interim business."